The global feline atopic dermatitis treatment market is slated to expand at a positive 4.5% CAGR during the assessment period (2022 to 2032). Sales in the feline atopic dermatitis treatment market are expected to reach USD 5 Billion by the end of 2022. Growth in the market is primarily attributed to the rising adoption of cats as a companion pet across the globe.
| Report Attribute | Details |
|---|---|
| Feline Atopic Dermatitis Treatment Market Estimated Growth Rate (2022 to 2032) | 4.5% CAGR |
| Feline Atopic Dermatitis Treatment Market Estimated Size (2022) | USD 5 billion |
| Feline Atopic Dermatitis Treatment Market Projected Size (2032) | USD 7 billion |
Atopic dermatitis is the inflammation of skin witnessed in cats and is caused by causative allergens, which are either inhaled or caused by skin contact. With rising adoption of cats as pet, the prevalence of feline atopic dermatitis is surging across the globe.
According to Canadian Veterinary Journal, prevalence of atopic dermatitis in cats was reported to be over 12.5% in feline. As atopy causes distress, fur loss, and discomfort in cats, the need for feline atopic dermatitis treatment is expected to burgeon over the forecast period.
To curb the rising incidence of atopy in cats, professionals are using steroids and antibiotics to reduce the itchiness and fur loss. As steroids are cost-effective and effective, the corticosteroids segment is expected to gain traction, as per Future Market Insights (FMI).
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
One of the primary factors driving the growth in the market is rising adoption of companion animals such as dogs and cats across the globe. According to the National Kitten Coalition statistics, around 1.3 million cats are adopted every year as pets across the globe.
With rising adoption of cats, prevalence of skin allergies and other diseases in feline will improve the demand for feline atopic dermatitis treatments. Besides this, increasing number of veterinarians in developed regions such as North America and Europe will further spur the growth in the market.
With increasing number of pet adoption across the globe, prevalence of several animal diseases is also surging. Every year over 7.6 million companion animals such as cats and dogs enter shelter across the globe. Among which, over 3.4 million felines are adopted, as per the National Kitten Coalition.
However, lack of novel treatment in emerging economies such as Brazil, Argentina, India, and others might limit the growth in the market. Due to the lack of treatment, the chance of reoccurrence of atopic dermatitis is high. This might hamper the feline atopic dermatitis treatment market.
Another factor hampering the demand in the market is treatment cost of feline atopic dermatitis treatment. As per the study, the cost of this treatment is generally high, which might affect the sales in Latin America and Middle East & Africa.
Additionally, long-term side-effects of corticosteroids might limit the sales of oral treatment. This is expected to hinder the growth in the market.
Asia Pacific feline atopic dermatitis treatment market is anticipated to witness modest growth between 2022 and 2032, opines Future Market Insights (FMI). Asia Pacific is considered to be the emerging feline atopic dermatitis market owing to the rising pet ownership of cats and dogs in India, China, and Japan.
As per FMI, India is expected to spearhead the growth in Asia Pacific market over the forecast period. This is due to the increasing number of veterinarians in the country coupled with rising adoption of cats. Moreover, rise in the number of research organizations to develop novel medicines and treatment procedures in China will boost the market.
Further, greater penetration of leading players in India and adequate availability of treatment for pet animals will improve the demand in Asia Pacific market over the upcoming decade.
As per FMI, the USA is expected to account for significant share in North America feline atopic dermatitis treatment market. Around 1.9 million pets were adopted in 2020 across the USA, according to the Pet Adoption Statistics. Out of which, there were 1.1 million cats and the number is projected to increase over the coming decade.
With growth in the number of pet adoption, prevalence of skin treatment among feline is also surging. This is expected to create lucrative growth opportunities for feline atopic dermatitis treatment market in North America.
Further, availability of reimbursement policies, growing number of veterinarians, and early adoption of novel medication and treatment in the USA will propel the demand in the North America market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Some of the leading manufacturers of feline atopic dermatitis treatment include Bayer AG, Pfizer Inc., Boehringer Ingelheim International GmbH Novartis AG, Eli Lily Company, Sanofi, Bristol-Myers Squibb Company, and Bausch Health Companies Inc. among others.
Key players in the feline atopic dermatitis treatment market are relying on merges and collaborative agreements to increase their revenue. They are also investing in research and development activities to develop novel treatments and medicines to expand their product portfolio.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.5% from 2022 to 2032 |
| Estimated Market Size (2022) | ~USD 5 billion |
| Projected Market Size (2032) | ~USD 7 billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered |
North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled |
Bausch Health Companies Inc.; Bayer AG; Pfizer Inc.; Novartis AG; Eli Lily Company; Sanofi; Bristol-Myers Squibb Company; Boehringer Ingelheim International GmbH |
| Customization | Available Upon Request |
As per FMI, the global feline atopic dermatitis treatment market demand is slated to increase at 4.5% CAGR during the forecast period.
North America is anticipated to dominate the global feline atopic dermatitis treatment market over the forecast period (2022 to 2032).
Overall demand in the feline atopic dermatitis treatment market is expected to exceed USD 5 Billion by the end of 2022.
| Estimated Size, 2024 | USD 15,048.6 million |
|---|---|
| Projected Size, 2034 | USD 45,501.6 million |
| Value-based CAGR (2024 to 2034) | 11.7% |
| Market Size, 2024 | USD 1,182.60 million |
|---|---|
| Market Size, 2034 | USD 1,620.50 million |
| Value CAGR (2024 to 2034) | 3.20% |
Explore Animal Health Therapeutics Insights
View Reports
Feline Atopic Dermatitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
